Based on the multidisciplinary expert consensus on managing GLP-1 GI side effects: While dehydration can affect anyone on GLP-1 medications, certain groups face higher risk: GI tolerability of semaglutide 2.4 mg (STEP 1-3 pooled analysis) 74% GI adverse events in semaglutide group vs 48% placebo
Tirzepatide at all doses was noninferior and superior to semaglutide
With retatrutide greater metabolic activation, some researchers suggest that higher-intensity resistance training may be better tolerated and more effective because the compound provides more metabolic support for recovery
Retrieved December 4, 2025, from Qi, Z., Guo, W., Zheng, S., Fu, C., Ma, Y., Pan, S., Liu, Q., & Yang, X
Express Scripts requires BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)